X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Encainide
2. Encainide Hydrochloride, (+-)-isomer
3. Encainide, (+)-isomer
4. Encainide, (-)-isomer
5. Enkaid
6. Mj 9067
7. Mj-9067
8. Mj9067
1. 66794-74-9
2. Encainide Hcl
3. Enkaid
4. Encainide (hydrochloride)
5. Encainide Hydrochloride [usan]
6. Mj 9067-1
7. Mj-9067
8. Encainidehydrochloride
9. 4-methoxy-2'-(2-(1-methyl-2-piperidyl)ethyl)benzanilide Hydrochloride
10. (+-)-2'-(2-(1-methyl-2-piperidyl)ethyl)-p-anisanilide Monohydrochloride
11. 4ch7j36n9s
12. Chebi:59880
13. 4-methoxy-n-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide;hydrochloride
14. (+/-)-4-methoxy-n-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide Hydrochloride
15. Mj-9067-1
16. Encainide Hydrochloride (usan)
17. 2-(2-{2-[(4-methoxybenzoyl)amino]phenyl}ethyl)-1-methylpiperidinium Chloride
18. 4-methoxy-n-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide Hydrochloride
19. Enkade; Enkaid;benzamide, 4-methoxy-n-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]-, Monohydrochloride (9ci); Benzamide, 4-methoxy-n-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]-, Monohydrochloride, (+/-)-
20. Ncgc00185765-01
21. Unii-4ch7j36n9s
22. Mfcd01667688
23. Dsstox_cid_28930
24. Dsstox_rid_83196
25. Dsstox_gsid_49004
26. Mls004712064
27. Schembl121261
28. Chembl2106155
29. Dtxsid2049004
30. Encainide Hydrochloride [mi]
31. Tox21_113498
32. Nsc299238
33. Akos025311581
34. Encainide Hydrochloride [mart.]
35. Encainide Hydrochloride [vandf]
36. Nsc-299238
37. Encainide Hydrochloride [who-dd]
38. Benzamide, 4-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, Monohydrochloride, (+-)-
39. Hy-12531
40. Smr002529683
41. Cas-66794-74-9
42. Cs-0011988
43. D03991
44. H11012
45. Encainide Hydrochloride, >=98% (hplc), Powder
46. Q27126935
47. 4-methoxy-2' -[2-(1-methyl- 2-piperidyl)athyl]benzanilid-hydrochlorid
48. (+/-)-2'-(2-(1-methyl-2-piperidyl)ethyl)-p-anisanilide Monohydrochloride
49. Benzamide, 4-methoxy-n-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-, Monohydrochloride, (+/-)-
| Molecular Weight | 388.9 g/mol |
|---|---|
| Molecular Formula | C22H29ClN2O2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 388.1917559 g/mol |
| Monoisotopic Mass | 388.1917559 g/mol |
| Topological Polar Surface Area | 41.6 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 434 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
Market Place
